C12N 2710/10371
Demonstrated in vivo effect
C12N2710/10371 (Demonstrated in vivo effect) appears on 76 US grants and 141 published applications in this corpus.
Search patents in C12N- Granted patents
- 76
- Published applications
- 141
- Assignees
- 66
- Inventors
- 238
- Latest grant
- 12 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 3 |
| 2005 | 0 | 2 |
| 2006 | 0 | 1 |
| 2007 | 0 | 2 |
| 2008 | 0 | 1 |
| 2009 | 2 | 4 |
| 2010 | 1 | 6 |
| 2011 | 0 | 4 |
| 2012 | 4 | 6 |
| 2013 | 2 | 6 |
| 2014 | 0 | 4 |
| 2015 | 2 | 7 |
| 2016 | 5 | 7 |
| 2017 | 5 | 8 |
| 2018 | 3 | 13 |
| 2019 | 9 | 10 |
| 2020 | 6 | 11 |
| 2021 | 6 | 10 |
| 2022 | 12 | 12 |
| 2023 | 4 | 8 |
| 2024 | 7 | 10 |
| 2025 | 6 | 4 |
| 2026 | 2 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Modified oncolytic adenoviruses12 May 2026US 12,622,935 B2Valo Therapeutics Oy
- AD36E4ORF1: a therapeutic treatment for Alzheimer's disease6 Jan 2026US 12,514,901 B2Texas Tech University System
- Immunogenic compositions and uses thereof18 Nov 2025US 12,472,244 B2Board of Regents, The University of Texas System
- Immunogenic compositions and uses thereof14 Oct 2025US 12,440,550 B2Board of Regents, The University of Texas System
- Methods and compositions for producing an adenovirus vector for use with multiple vaccinations29 Jul 2025US 12,370,250 B2Etubics Corporation
- Covalently-modified steroid acid-peptides having enhanced stability and/or biological activity23 Jul 2026US 2026/0207765 A1Defence Therapeutics Inc.
- Oncolytic adenovirus compositions with enhanced replication properties18 Jun 2026US 2026/0167940 A1The Salk Institute for Biological Studies
- Modified adenoviruses24 Jul 2025US 2025/0236884 A1Gritstone Bio, Inc.
- Immunomodulatory fusion proteins6 Mar 2025US 2025/0074967 A1EpicentRx, Inc.
- Adenoviral vector system for gene delivery20 Feb 2025US 2025/0057935 A1
Most cited
By later US patents
- Compositions and methods for the therapy and diagnosis of lung cancer57US 7,749,505 B2Corixa Corporation · 2010
- Methods for the detection of cervical cancer56US 7,579,160 B2Corixa Corporation · 2009
- Compositions and methods for the therapy and diagnosis of lung cancer56US 7,585,506 B2Corixa Corporation · 2009
- Simian adenoviruses SAdV-36, -42.1, -42.2, and -44 and uses thereof56US 8,470,310 B2The Trustees of the University of Pennsylvania · 2013
- Simian adenoviruses SAdV-36, -42.1, -42.2, and -44 and uses thereof46US 9,597,363 B2The Trustees of the University of Pennsylvania · 2017